Extrapyramidal symptoms

[Extrapyramidal symptoms]] (EPS), are side effects typically associated with certain medications, particularly antipsychotics and neuroleptics. These symptoms reflect dysfunction in the extrapyramidal system, a neural network in the brain that controls motor function and is regulated by the basal ganglia, a group of structures in the brain's cerebral cortex.

Clinical Presentation

Extrapyramidal symptoms encompass a range of movement disorders, including dystonia, akathisia, parkinsonism, and tardive dyskinesia.

• Dystonia is characterized by persistent spasms and muscle contractions that can cause abnormal postures or repetitive movements.
• Akathisia is a state of restlessness that manifests as an inability to stay still, often accompanied by a subjective sense of discomfort.
• Parkinsonism is a syndrome mimicking Parkinson’s disease, with symptoms such as bradykinesia (slowness of movement), rigidity, and tremor.
• Tardive dyskinesia is a condition marked by irregular, jerky movements, often affecting the face.
• EPS can be acute, presenting shortly after the initiation of treatment, or chronic, developing after prolonged use of the offending medication.

Etiology and Risk Factors

EPS are primarily associated with the use of drugs that block dopamine receptors in the brain, such as antipsychotics and some antiemetics. First-generation or "typical" antipsychotics, like haloperidol and chlorpromazine, carry a higher risk of EPS compared to second-generation or "atypical" antipsychotics.

Individual susceptibility to EPS may also be influenced by factors such as age, sex, and genetic predisposition.

Diagnosis and Management

The diagnosis of EPS is primarily clinical, based on the presentation of characteristic symptoms and a history of exposure to a causative drug.

The management of EPS involves reducing the dose of the causative drug, switching to a drug with a lower risk of EPS, or using adjunctive treatments like anticholinergic medications or dopamine agonists. In severe cases, hospitalization may be necessary.

Impact on Treatment Adherence

EPS can significantly impact adherence to medication regimens. In clinical trials, they are a common reason for participant dropouts. Thus, it is crucial for healthcare providers to monitor for EPS and manage them promptly to optimize patient outcomes.

References

• [1] Stahl, S. M. (2018). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications. Cambridge University Press.
• [2] Kane, J. M., & Correll, C. U. (2020). Optimizing treatment choices to improve adherence and outcomes in schizophrenia. Journal of Clinical Psychiatry, 81(5).

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia